ATRIVA THERAPEUTICS
Atriva Therapeutics is a biopharmaceutical company which aims to develop new antiviral therapies against different respiratory viral infections. Atriva Therapeutics completed preclinical development of ATR-002 and recently filed a request for scientific advice from a European regulatory authority to provide guidance on the executed preclinical development program and the planned ATR-002 Phase I study in healthy volunteers.
ATRIVA THERAPEUTICS
Social Links:
Industry:
Biopharma Biotechnology Pharmaceutical Therapeutics
Founded:
2015-01-01
Address:
Tübingen, Baden-Wurttemberg, Germany
Country:
Germany
Website Url:
http://www.atriva-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+4970718597673
Total Funding:
8.6 M EUR
Technology used in webpage:
IPhone / Mobile Compatible Viewport Meta Apple Mobile Web Clips Icon Google Font API WordPress Organization Schema Sitelinks Search Box Person Schema Common Name Invalid Product Schema
Similar Organizations
Aclaris Therapeutics
Aclaris Therapeutics is a specialty pharmaceutical company engaged in developing dermatologic therapies.
Reata Pharmaceuticals
Reata Pharmaceuticals is a biopharmaceutical company that develops drugs for cancer, inflammation, and neurodegenerative diseases.
SunRock
SunRock is a biotech company that engages in the development of antibodies against highly invasive tumors.
Current Employees Featured
Founder
Investors List
Meneldor
Meneldor investment in Debt Financing - Atriva Therapeutics
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Debt Financing - Atriva Therapeutics
Meneldor
Meneldor investment in Series A - Atriva Therapeutics
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Series A - Atriva Therapeutics
KreaMedica
KreaMedica investment in Series A - Atriva Therapeutics
BIF Partners
BIF Partners investment in Seed Round - Atriva Therapeutics
HTGF | High-Tech Gruenderfonds
HTGF | High-Tech Gruenderfonds investment in Seed Round - Atriva Therapeutics
Official Site Inspections
http://www.atriva-therapeutics.com
- Host name: CIOERZXSP03PLK.cionix.de
- IP address: 194.121.56.65
- Location: Germany
- Latitude: 51.2993
- Longitude: 9.491
- Timezone: Europe/Berlin
More informations about "Atriva Therapeutics"
Company | Atriva - Atriva Therapeutics
Atriva Therapeutics is a biopharmaceutical company pioneering the development of first-in-class host-cell-targeting antiviral and immunomodulatory therapies. The company was set up by a …See details»
Management | Atriva - Atriva Therapeutics
Atriva Therapeutics GmbH. Am Klopferspitz 19 82152 Planegg/Martinsried +49 (0)69 9999 162 10 [email protected]. Impressum Datenschutzerklärung ...See details»
Atriva Therapeutics - Crunchbase Company Profile
Atriva Therapeutics may be growing as evidenced by its involvement in a significant corporate transaction. The company has entered into an exclusive letter agreement for a reverse takeover transaction with Biocure Technology, …See details»
Atriva Therapeutics - Org Chart, Teams, Culture & Jobs - The Org
Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading scientists in viral …See details»
Atriva Therapeutics Company Profile 2024: Valuation, Funding ...
Atriva Therapeutics Inc is a biopharmaceutical company developing host-cell-targeting antiviral and immunomodulatory therapies. It aims to develop novel, highly efficacious and safe …See details»
Atriva Therapeutics GmbH - DevelopmentAid
Oct 11, 2024 Atriva Therapeutics, founded in 2015, is a biopharmaceutical company specifically pioneering the development of host-targeting antiviral therapies set up by a team of leading …See details»
Biocure Technology Inc. enters into exclusive Letter Agreement to ...
Sep 18, 2023 VANCOUVER, British Columbia, September 18, 2023 -- Biocure Technology Inc. (“CURE” or the “Company”) (CSE: CURE) announces that it has entered into an exclusive …See details»
Atriva Therapeutics GmbH | European Clinical Trials Information …
Atriva Therapeutics’ expertise lies in the development of small molecule drugs that target viral replication, with a particular focus on the MEK pathway. The company’s lead candidate, ATR …See details»
Biocure Technology Inc. Enters into Exclusive Letter Agreement to ...
Vancouver, British Columbia--(Newsfile Corp. - September 18, 2023) - Biocure Technology Inc. (CSE: CURE) ("CURE" or the "Company") announces that it has entered into an exclusive …See details»
Atriva Therapeutics appoints Christian Pangratz as Chief Executive ...
Jan 16, 2023 About Atriva Therapeutics. Atriva Therapeutics’ mission is to develop an antiviral therapy platform against severe respiratory and systemic diseases with a high unmet medical …See details»
Atriva Therapeutics - VentureRadar
" ATRIVA aims to develop new antiviral therapies against different respiratory viral infections. Founded in 2015, ATRIVA attracted seasoned experts in virology and drug development to …See details»
Atriva Therapeutics Announces Exclusive Letter Agreement for …
Sep 18, 2023 Atriva Therapeutics and Canadian Biocure Technologies, Inc. entered into an exclusive letter agreement for a reverse takeover transaction. Upon successful completion of …See details»
Atriva Therapeutics: a quantum leap in antiviral respiratory
Atriva Therapeutics 0 Atriva Therapeutics Rainer Lichtenberger, President and CEO, Atriva Therapeutics GmbH, Tübingen, Germany, Tel: +49 7071 859 7673, www.atriva-therapeutics.comSee details»
Atriva Therapeutics: transforming antiviral therapies - Nature
Atriva Therapeutics, a biopharmaceutical company based in Tübingen, Germany, is set to revolutionize the treatment of influenza, COVID-19 and other potentially life-threatening …See details»
Atriva Therapeutics’ lead candidate Zapnometinib shows …
Nov 9, 2021 Tübingen and Frankfurt, Germany, November 09, 2021 – Atriva Therapeutics GmbH, a biopharmaceutical company pioneering the development of host-targeting antiviral …See details»
Atriva Therapeutics: a quantum leap in antiviral respiratory therapies
Atriva Therapeutics is developing a unique portfolio of broadly active and efficacious antiviral drugs based on MEK inhibitors, including its lead candidate ATR-002, which maySee details»
Efficacy and safety of zapnometinib in hospitalised adult patients …
Oct 4, 2023 The Sponsor/funders (Atriva Therapeutics) were involved in the trial design, trial management, data collection, data analysis, data interpretation, and report writing. The …See details»
Indications | Atriva - Atriva Therapeutics
On December 29th, 2020, Atriva Therapeutics obtained RESPIRE trial approval in COVID-19 patients from German authorities. In April 2021, the company announced the dosing of the first …See details»
The Atriva Approach | Atriva - Atriva Therapeutics
The Atriva Approach Atriva Therapeutics pursues a novel and unique approach. By combining antiviral and immunomodulatory activity via the downregulation of MEK in host cells, Atriva …See details»